Wegovy vs. Zepbound: What the FDA Labels Actually Say (and Who Each Drug Is Approved For)
The real difference isn't just the mechanism — it's the indications. Here's what each label officially covers.
I now have everything I need. Let me write the article.
Most people asking "Wegovy or Zepbound?" are really asking the wrong question. The better question is: what is each drug actually approved to do? The answer is more interesting — and more specific — than most comparison posts let on.
Two Different Drugs, Two Different Mechanisms
Start with the basics. Wegovy's active ingredient is semaglutide, a GLP-1 receptor agonist made by Novo Nordisk. The FDA's Wegovy label describes it as a drug that mimics a gut hormone to reduce appetite and slow gastric emptying.
Zepbound's active ingredient is tirzepatide, made by Eli Lilly. The FDA's Zepbound label classifies it as a dual agonist — it hits both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. That second target is the meaningful difference on paper. Whether it matters clinically for you is a conversation for your prescriber.
Who Each Drug Is Officially Approved For
This is where things get specific, and where a lot of online comparisons gloss over the details.
Wegovy is approved for a notably wider set of indications. According to the FDA label, it is indicated for:
- Adults and pediatric patients aged 12 and older with obesity
- Adults who are overweight with at least one weight-related condition (like high blood pressure or high cholesterol)
- Adults with established cardiovascular disease and obesity or overweight — specifically to reduce the risk of major adverse cardiovascular events (CV death, non-fatal heart attack, or non-fatal stroke)
- Adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) with moderate-to-advanced liver fibrosis — though the FDA label notes this indication was granted under accelerated approval and may be contingent on confirmatory trial results
That cardiovascular indication is a big deal. It's one of the few weight-loss drugs with a label claim tied directly to heart outcomes, not just the scale.
Zepbound has its own distinct edge. Per the FDA's Zepbound label, it is approved for:
- Adults with obesity, or overweight adults with at least one weight-related condition
- Adults with obesity who have moderate to severe obstructive sleep apnea (OSA)
That OSA indication is unique — no other weight-loss injectable currently carries it. MedlinePlus describes obstructive sleep apnea as a common disorder where the airway collapses or becomes blocked during sleep, and notes that being overweight is a primary risk factor. If you have both obesity and a diagnosed sleep apnea condition, Zepbound's label speaks directly to your situation in a way Wegovy's does not.
One important note from the Zepbound label: it explicitly states that coadministration with any other GLP-1 receptor agonist is not recommended.
What the Side Effect Profiles Have in Common
Both labels list a nearly identical set of most common adverse reactions. According to Wegovy's FDA label, reactions reported in 5% or more of adults or pediatric patients include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, hair loss, and gastroesophageal reflux disease. Zepbound's label lists the same core GI symptoms, plus injection site reactions.
Both labels carry warnings about acute pancreatitis, gallbladder disease, risk of thyroid C-cell tumors (seen in animal studies), and hypoglycemia risk when combined with insulin or insulin secretagogues. These are reported associations from clinical trials — not confirmed causal outcomes for every person who takes them — but they're the reason your prescriber needs to know your full medical history before you start either one.
What the Research Says About Head-to-Head Weight Loss
There's now direct comparison data. A 2024 study published in JAMA Internal Medicine by Rodriguez et al. compared real-world weight loss outcomes between semaglutide and tirzepatide in adults with overweight or obesity. A 2024 systematic review and network meta-analysis in Diabetologia by Karagiannis et al. looked at tirzepatide vs. semaglutide across randomized controlled trials in type 2 diabetes. Both pieces of research exist — but interpreting which number applies to your body, your health history, and your goals is exactly why these decisions belong with a clinician, not a blog.
The key takeaway from the research landscape is that tirzepatide's dual mechanism has generated significant clinical interest — but label indications and your individual eligibility are the starting point, not the finish line.
What This Means for You
- Wegovy is the only one of the two with an FDA-approved cardiovascular risk-reduction indication and is currently approved for patients as young as 12. If heart disease or MASH are part of your picture, that label language matters.
- Zepbound is the only one with an FDA-approved sleep apnea indication. If you have diagnosed moderate-to-severe OSA and obesity, that's a meaningful clinical distinction to bring up with your doctor.
- Both drugs share a nearly identical GI side-effect profile and the same core warnings. The mechanism differs; the tolerability conversation is similar.
Not medical advice. Talk to your prescriber about your specific health history, eligibility, and which option — if any — is right for you.
